| Patent application number | Description | Published |
|---|
| 20100092541 | COMPOSITIONS AND METHODS FOR TREATMENT OF EYE DISORDERS - The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists. | 04-15-2010 |
| 20100093693 | MODULATORS OF CELLULAR ADHESION - The present invention provides compounds having formula (I); | 04-15-2010 |
| 20100179123 | THIENOPYRIMIDINES USEFUL AS AURORA KINASE INHIBITORS - The present invention provides compounds having the formula: | 07-15-2010 |
| 20110124625 | Modulators of Cellular Adhesion - The present invention provides compounds having formula (I): | 05-26-2011 |
| 20110124669 | Modulators of Cellular Adhesion - The present invention provides compounds having formula (I): | 05-26-2011 |
| 20110165228 | Compositions and Methods for Treatment - The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists. | 07-07-2011 |
| 20110165229 | Compositions and Methods for Treatment - The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists. | 07-07-2011 |
| 20120035154 | Modulators of Cellular Adhesion - The present invention provides compounds having formula (I): | 02-09-2012 |
